Arthneeti
All Q4 FY26 results →
SM

Shilpa Medicare Ltd

Q4 FY26Pharmaceuticals & Biotechnology

Shilpa Medicare Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹815
Market cap₹14.1K Cr
P/E49.6
Updated23 Aug 2026
Read5 min read

The short version

FY27 growth outlook is positive with scaling opportunities, especially in formulation and biologics. - European formulation business expects healthy growth, with multiple product launches planned in FY27. - Biologics segment projected to grow significantly in FY27 and FY28, driven by CDMO business, licensing income, and new product launches like Nivolumab and ADC. - API oncology product expansion underway, with steady growth expected rather than steep increase. - NorUDCA product shows steep QoQ growth post-launch; further scaling expected in FY27. - U.S. EBITDA margins are currently at 29% with ambitions to reach 35% over the next 1-2 years, though immediate achievement is uncertain due to ongoing reinvestments for growth (Page 8, 18).

From Shilpa Medicare Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • FY27 growth outlook is positive with scaling opportunities, especially in formulation and biologics.
  • European formulation business expects healthy growth, with multiple product launches planned in FY27.
  • Biologics segment projected to grow significantly in FY27 and FY28, driven by CDMO business, licensing income, and new product launches like Nivolumab and ADC.
  • API oncology product expansion underway, with steady growth expected rather than steep increase.
  • NorUDCA product shows steep QoQ growth post-launch; further scaling expected in FY27.
  • U.S. revenues expected to grow, focusing on super specialty products despite discontinuation of some generics.
  • EBITDA margins targeted to improve toward 35% over 1-2 years as operational leverage builds with growth.

2 more points from Shilpa Medicare Ltd's call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

See what Shilpa Medicare Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • FY26 capex was INR361 crores, funded primarily via internal accruals and deployed in key verticals: API, CDMO, and albumin facility.
  • For the current financial year, no significant increase in capex is expected compared to last year; capex will continue to sustain at similar levels.
  • Future investments focus on near-term and mid-term revenue-generating opportunities; no long-term, high gestation projects planned.

2 more points from Shilpa Medicare Ltd's call on capex

Pro opens every point from 15K+ earnings calls

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Shilpa Medicare Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript does not explicitly provide precise figures or detailed commentary on the current or expected order book or pending orders for Shilpa Medicare Limited. However, some relevant insights can be inferred: - The company continues to demonstrate strong revenue growth with a healthy pipeline of molecules and products in formulation, biologics, and API segments. - Several products are under development or awaiting approvals, including biologics entering human global studies expected to commercialize by FY29. - Operations are supported by both in-house manufacturing and third-party CMOs; no capacity crunch is currently seen.

2 more points from Shilpa Medicare Ltd's call on order book

Pro opens every point from 15K+ earnings calls

Shilpa Medicare Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹437 Cr, net profit ₹108 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Shilpa Medicare Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pha. (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn Ltd (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Shilpa Medicare Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Shilpa Medicare Ltd Q4 FY26 results?

FY27 growth outlook is positive with scaling opportunities, especially in formulation and biologics. - European formulation business expects healthy growth, with multiple product launches planned in FY27. - Biologics segment projected to grow significantly in FY27 and FY28, driven by CDMO business, licensing income, and new product launches like Nivolumab and ADC. - API oncology product expansion underway, with steady growth expected rather than steep increase. - NorUDCA product shows steep QoQ growth post-launch; further scaling expected in FY27. - U.S. EBITDA margins are currently at 29% with ambitions to reach 35% over the next 1-2 years, though immediate achievement is uncertain due to ongoing reinvestments for growth (Page 8, 18).

What is Shilpa Medicare Ltd share price analysis?

Shilpa Medicare Ltd currently shows a neutral. The stock trades at a P/E of 49.6 with a market cap of ₹14,116 Cr. Investors should review the full earnings analysis for detailed insights.

Is Shilpa Medicare Ltd planning capital expenditure?

FY26 capex was INR361 crores, funded primarily via internal accruals and deployed in key verticals: API, CDMO, and albumin facility.

Keep Shilpa Medicare Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.